- Conditions
- Graft-versus-host Disease (GVHD)
- Interventions
- Ruxolitinib, Extracorporeal photopheresis (ECP), Low-dose methotrexate (MTX), Mycophenolate mofetil (MMF), mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus), Infliximab, Rituximab, Pentostatin, Imatinib, Ibrutinib
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 38
- States / cities
- Tucson, Arizona • Duarte, California • La Jolla, California + 28 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2617–2640
of 29,142
matching trials from the live ClinicalTrials.gov search.
- Conditions
- HIV Infections
- Interventions
- Lamivudine/Zidovudine, Lamivudine, Zidovudine
- Drug
- Lead sponsor
- Glaxo Wellcome
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 6
- States / cities
- Beverly Hills, California • Los Angeles, California • Chapel Hill, North Carolina + 3 more
- Conditions
- Major Depression
- Interventions
- Lamotrigine, Ketamine, Riluzole
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- Interventions
- VX-407, LNG/EE, NGM/EE, NET/EE, DRSP/EE
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 74 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Healthy
- Interventions
- Ticagrelor Oral Tablet - Pre-Treatment, Aspirin (ASA) Oral Tablet - Pre-Treatment, Bentracimab (PB2452) Infusion, Placebo (0.9% Sodium chloride) infusion
- Drug
- Lead sponsor
- SFJ Pharmaceuticals, Inc.
- Industry
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 207 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 13
- States / cities
- Rogers, Arkansas • Cypress, California • San Diego, California + 9 more
- Conditions
- Alcoholic Intoxication, Neurobehavioral Manifestations
- Interventions
- Alcohol, Placebo
- Drug · Other
- Lead sponsor
- Boston University
- Other
- Eligibility
- 21 Years to 30 Years
- Enrollment
- 239 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2009
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Relapsed/Refractory KMT2A-r Acute Leukemia, Relapsed/Refractory NUP98-r Acute Leukemia, Relapsed/Refractory NPM1-m Acute Leukemia
- Interventions
- Ziftomenib, Cytarabine, Fludarabine
- Drug
- Lead sponsor
- PedAL BCU, LLC
- Other
- Eligibility
- 0 Years to 21 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2033
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 8 more
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Graft cell infusion, Tacrolimus, Mycophenolate mofetil, G-CSF, CIML NK cell infusion, ALT-803, Leukapheresis
- Procedure · Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2028
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Hip Dysplasia, Femoroacetabular Impingement, Acetabular Labrum Tear
- Interventions
- ropivicaine, clonidine, Epinephrine, Noropin
- Drug
- Lead sponsor
- The Hawkins Foundation
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Greenville, South Carolina
- Conditions
- Nerve Injury
- Interventions
- Temporary Peripheral Nerve Stimulation System, Sham Temporary Peripheral Nerve Stimulation System
- Device
- Lead sponsor
- Epineuron Technologies Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 110 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 6
- States / cities
- Gainesville, Florida • Orlando, Florida • New Orleans, Louisiana + 3 more
- Conditions
- Quality of Life, Injection Site Reaction, Adverse Drug Event, Systemic Reaction
- Interventions
- mRNA COVID-19, IIV4, Placebo (saline)
- Biological · Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- 5 Years and older
- Enrollment
- 348 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 3
- States / cities
- Baltimore, Maryland • Durham, North Carolina • Cincinnati, Ohio
- Conditions
- Advanced Solid Tumor
- Interventions
- CPI-200
- Drug
- Lead sponsor
- Coordination Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Grand Rapids, Michigan
- Conditions
- CAH - Congenital Adrenal Hyperplasia
- Interventions
- NBI-74788
- Drug
- Lead sponsor
- Neurocrine Biosciences
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 6
- States / cities
- Aurora, Colorado • Indianapolis, Indiana • Ann Arbor, Michigan + 3 more
- Conditions
- Glioblastoma
- Interventions
- 3-Dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Photon Beam Radiation Therapy, Proton Beam Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration, Temozolomide
- Radiation · Other · Drug
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 429 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2030
- U.S. locations
- 230
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 179 more
- Conditions
- Solid Tumor, Adult
- Interventions
- HL-085
- Drug
- Lead sponsor
- Kechow Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 5
- States / cities
- San Marcos, California • Las Vegas, Nevada • Canton, Ohio + 2 more
- Conditions
- Glioblastoma, Glioblastoma With Primitive Neuronal Component, Gliosarcoma, Malignant Glioma, Oligodendroglial Component Present
- Interventions
- Plerixafor, Temozolomide, Whole-Brain Radiotherapy (WBRT), Radiation Therapy
- Drug · Radiation
- Lead sponsor
- Lawrence D Recht
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- treprostinil diethanolamine
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2010
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Advanced Solid Tumors
- Interventions
- oral topotecan (SK&F-104864); lapatinib (GW572016)
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 2
- States / cities
- Rochester, Minnesota • Philadelphia, Pennsylvania
- Conditions
- Healthy Volunteers, Alzheimer Disease, Amyloid, Plaque, Amyloid, Plasma
- Interventions
- LY4560736, Placebo, Florbetapir F18, Florbetaben F 18
- Drug · Other
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 111 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 13
- States / cities
- Anaheim, California • Irvine, California • Los Alamitos, California + 10 more
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- BCNU 80mg/m2, TMZ 200mg/m2, radiation therapy, CCNU, BCNU 150mg/m2, BCNU 200mg/m2, TMZ 150mg/m2 six 6-week cycles, TMZ 150mg/m2 six 8-week cycles
- Drug · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2018
- U.S. locations
- 92
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Chico, California + 71 more
- Conditions
- Necrotizing Enterocolitis
- Interventions
- hydrocortisone, placebo
- Drug
- Lead sponsor
- Endeavor Health
- Other
- Eligibility
- 0 Days to 6 Months
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Evanston, Illinois
- Conditions
- Heroin Dependence, Opioid-Related Disorders, Substance-Related Disorders
- Interventions
- naltrexone, Placebo comparator
- Drug
- Lead sponsor
- National Institute on Drug Abuse (NIDA)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 174 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Crohn's Disease, Glycogen Metabolism, Inflammatory Bowel Disease (IBD)
- Interventions
- Empagliflozin
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Acute Monocytic Leukemia, Acute Myeloid Leukemia
- Interventions
- Azacitidine, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Cladribine, Cytarabine, Echocardiography, Lumbar Puncture, Multigated Acquisition Scan, Questionnaire Administration, Venetoclax
- Drug · Procedure · Other
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 2
- States / cities
- Miami, Florida • Portland, Oregon